China on course for 'massive' bio capacity shortfall

4 Nov 2019

A shortage of qualified personnel may be a drag factor in cell and gene therapies; in China 100,00L of capacity will need to be added every year to meet bio demand.

CPhI Worldwide has released the third part of its annual report focussed on bio in China and advanced biologicals.

China on course for 'massive' bio capacity shortfall

The report highlights growing opportunities for CDMOs in cell and gene therapies, as well as the needed capacity expansions to meet China’s burgeoning demand. Two annual report experts, Michael E. Ultee of Ulteemit BioConsulting and Vicky Qing Xia of BioPlan Associates, outline their expert perspectives on the likely opportunities and challenges in the coming 5 years.

A key theme at this year’s BioProduction – which runs alongside CPhI Worldwide and covers the entire spectrum of biopharmaceutical development and production – is the industry-wide focus on increasing productivity and quality. Encouragingly, Ultee forecasts that manufacturing in biopharma is now entering a new age of advanced processes whereby the overall cost of production could potentially begin to fall. He added that in 5 year’s time with the new processes now being applied, “manufacturing will become more efficient and cost savings will be delivered. Furthermore, economic pressure from biosimilars will push manufactures of these types of therapeutics towards lower costs.” In fact, Ultee suggests that many of the manufacturing challenges with biosimilars have been overcome and that hurdles to wider patient access are chiefly due to patent walls and litigation.

In advanced therapies, a lack of cell and gene expertise is now already causing potential issues in the clinical progress of many therapies, and there is a scramble for the most capable development partners, despite many CDMOs investing in capabilities. “There is already a shortage of CDMO services for this type of work. The high valuations shown by recent acquisitions of CDMOs, such as Brammer Bio and Paragon Bioservices, bear this out. I expect the shortage to continue for the next few years until more development and manufacturing scientists are trained in this new discipline and CDMOs expand their offerings,” added Ultee.

The implications of these new targets are that there will be a realignment over the next 1-3 years in the areas of cancer and rare-disease therapies – with a greater focus on cell and gene therapies rather than recombinant proteins.

In her near- and medium-term predictions, Vicky Qing Xia explores the huge changes currently underway in China, with single-use reactors rapidly on the rise. In fact, by 2021 at a CAGR of 16%, the biologics market in China may reach $50bn. Similarly, regulatory reforms – such as the MAH pilot – are seeing a bio services market growing even faster at above 30%, and forecast to reach $1.4bn by 2021. Qing Xia attributes this growth to several advanced players (primarily serving western customers) – notably WuXi Biologics, MabPlex, CMab and JHL biotech.

“The case for single-use bioreactors is particularly strong for two groups: early-stage mAb developers and biologics contract manufacturers. For mAb developers, single-use technology offers the key advantages of less capital investment during the project development stage as well as time-reduction in facility construction. Most mAb developers in China are working on biosimilar/biobetter versions of mAbs against several established targets including TNF-alpha, PD-1, Her-2 or EGFR with usually multiple companies for each target; the time to clinical development, therefore, can mean life or death for a project. Less capital investment during development is also extremely important for the small- to medium-sized biotech companies, as more often than not they are cash-strapped without enough resources for facility construction. With both mAb development and outsourced biomanufacturing on the rise in China, there is no surprise that single-use technology is getting more popular, enjoying double-digit (some even project over 30% CAGR) growth in recent years,” commented Qing Xia.

Qing Xia also believes there may be a good degree of flux in the market predictions, particularly as new products transition between clinical and commercial supply, adding: “Many of the VC-backed developers would seek IPO, and Chinese investors are known to value fixed assets such as land, facility over IP and product portfolio. We see many developers outsource pilot-scale production, but they would then plan to build their own facilities when their project goes to late clinical stage.”

Tara Dougal, Head of Content at Informa, added: “Our experts' analysis shows we are at a significant point for the supply chain, as new technologies help to bring about improved manufacturing processes. It is also a big focus at both CPhI Worldwide and BioProduction this year. Much of our content and, of course, our networking opportunities are designed to empower both exhibitors and attendees to meet partners that will help them prepare and deliver new solutions to help the industry expand in the next few years. In addition, P-MEC is also showcasing all of the global technologies to help deliver new manufacturing methodologies and sustain the growth predicted in contract services for both solid dose and biological drugs.”

Read More

Related news

Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
Europe predicted to surpass the US in biologic manufacturing capacity by 2023

Europe predicted to surpass the US in biologic manufacturing capacity by 2023

6 Nov 2019

Demand for biological manufacturing is growing faster than capacity growth.

Read more 
German pharma benefiting from a Brexit boost?

German pharma benefiting from a Brexit boost?

24 Oct 2019

Germany establishes itself as Europe's leading pharma market in 2019.

Read more 
The talk of the show?

The talk of the show?

23 Oct 2019

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPhI WW.

Read more 
‘FDA should withdraw ANDAs’ says expert

‘FDA should withdraw ANDAs’ says expert

21 Oct 2019

CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Read more 
Cytel to hold Complex Innovative Trial Design Symposium

Cytel to hold Complex Innovative Trial Design Symposium

18 Oct 2019

Experts to discuss innovative solutions to rare disease clinical trials.

Read more 
Finalists announced for this year's CPhI Worldwide Awards

Finalists announced for this year's CPhI Worldwide Awards

17 Oct 2019

The winners’ shortlist is packed with 40 of the industry’s most innovative companies and individuals who are shaping the future of pharma.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
Industry on the brink of a new age of smart pharma manufacturing

Industry on the brink of a new age of smart pharma manufacturing

27 Sep 2019

Report predicts tomorrow’s biggest industry winners will need to invest now ahead of the curve.

Read more